Method for predicting Pemetrexed chemotherapy using EXO1 polymorphism

A biomarker using the EXO1 rs1047840 polymorphism addresses variability in Pemetrexed treatment response by predicting therapeutic effect and prognosis in lung adenocarcinoma, improving personalized treatment outcomes.

KR103044494B1Active Publication Date: 2026-11-06KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
KR1020230082462
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-06-27
Publication Date
2026-11-06
Estimated Expiration
2043-06-27

AI Technical Summary

Technical Problem

Existing treatments for non-small cell lung cancer with Pemetrexed show significant variability in therapeutic effect and prognosis due to individual genetic differences, particularly in lung adenocarcinoma patients, necessitating a biomarker to predict response and prognosis accurately.

Method used

Development of a biomarker using the EXO1 rs1047840 polymorphism to predict the therapeutic effect and prognosis of Pemetrexed chemotherapy by identifying microRNA target site polymorphisms through crosslinking, ligation, and sequencing (CLASH) studies, utilizing a polynucleotide and polypeptide markers.

Benefits of technology

The biomarker effectively predicts the therapeutic effect and prognosis of Pemetrexed in lung adenocarcinoma patients by analyzing the EXO1 rs1047840G>A polymorphism, enhancing personalized treatment strategies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112023070562795-PAT00002_ABST
    Figure 112023070562795-PAT00002_ABST
Patent Text Reader

Abstract

The present invention relates to a marker for predicting the therapeutic effect or prognosis of Pemetrexed for non-small cell lung cancer (NSCLC) using a single nucleotide polymorphism (SNP) of the EXO1 gene, a composition for predicting the therapeutic effect or prognosis of Pemetrexed for NSCLC using the same, a kit for predicting the therapeutic effect or prognosis of Pemetrexed for NSCLC, a microarray, and a method for predicting the therapeutic effect or prognosis. The technology according to the present invention can evaluate the therapeutic effect of Pemetrexed for patients with NSCLC, and enhance the therapeutic effect of NSCLC patients by providing means for evaluating treatment methods through prognosis prediction and by targeting the treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a method for predicting Pemetrexed anticancer chemotherapy using the polymorphism of EXO1. Background Technology

[0002] Lung cancer is one of the leading causes of cancer death, accounting for 30% of cancer-related deaths worldwide. More than 75% of all lung cancers are non-small cell lung cancer (NSCLC), with an average 5-year survival rate of 15%.

[0003] Recently, the standard strategy for chemotherapy in non-small cell lung cancer involves selecting different drugs based on histological type. Particularly in the treatment of lung adenocarcinoma, the most frequent type of non-small cell lung cancer, Pemetrexed offers a primary choice with superior efficacy and fewer side effects compared to squamous cell carcinoma. However, significant differences exist in treatment response, duration of effect, and prognosis among patients treated with Pemetrexed.

[0004] Pemetrexed is an antifolate agent that is one of the most frequently used chemotherapy agents for patients with non-segmented non-small cell lung cancer (NSCLC). It interferes with cell replication and growth by inhibiting the synthesis of DNA and RNA by targeting three enzymes involved in the synthesis of purines and pyrimidines: thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).

[0005] miRNA (microRNA) is a small (containing about 22 nucleotides) single-stranded non-coding RNA molecule that functions as an endogenous negative regulator by binding to the 3'-UTR of target mRNA to induce degradation or translation inhibition of the target, and comprehensive miRNA profiling shows that miRNA is involved in biological processes such as cell division and death, cell metabolism, intracellular signaling, and immunity, as well as being involved in the development and progression of various human cancers.

[0006] miRNA target prediction methods have focused on standard (seed-based) target sites; however, due to their function in regulating gene expression, single nucleotide polymorphisms (SNPs) in miRNA binding sites are recently being used as cancer biomarkers to predict cancer risk, treatment response, and patient prognosis.

[0007] Single nucleotide polymorphisms (SNPs) are the most common form of human genetic variation, referring to a change in a sequence of nucleotides consisting of A, T, G, and C within the genome. SNPs account for approximately 90% of variations occurring in the human genome, and since individuals with similar traits or pedigrees share identical or similar SNP patterns, they can be used in clinical settings as indicators to predict an individual's susceptibility to disease, as well as to predict the efficacy and side effects of drugs. In particular, the importance of miRNA target site polymorphisms is being highlighted following the recent discovery that the key mechanism of post-transcriptional regulation of SNPs in the 3'-UTR is linked to miRNA gene targeting.

[0008] Meanwhile, previous studies have focused on the relationship between EXO1 polymorphisms, particularly rs1047840, and the risk of lung cancer, specifically the association between EXO1 rs1047840 and the survival rate of lung cancer patients, but the therapeutic and prognostic effects of targeted anticancer therapy with EXO1 rs1047840, particularly Pemetrexed for lung adenocarcinoma, are unknown.

[0009] Accordingly, the inventors completed the present invention by developing a biomarker that predicts the therapeutic effect or prognosis of Pemetrexed by identifying EXO1rs1047840 as a polymorphism with high functional priority among gene polymorphisms at locations where transcriptome-wide miRNA-target pairs exist through crosslinking, ligation, and sequencing of hybrid (CLASH) studies. The problem to be solved

[0010] The object of the present invention is to provide a polymorphic biomarker of a microRNA target site capable of predicting the therapeutic effect or prognosis of the pemetrexed.

[0011] Another objective of the present invention is to provide a composition for predicting (diagnosing) the therapeutic effect or prognosis of a lung cancer patient using Pemetrexed, comprising the marker.

[0012] Another objective of the present invention is to provide a microarray for predicting the effect of Pemetrexed treatment or prognosis (diagnosis) of a lung cancer patient comprising the marker.

[0013] Another objective of the present invention is to provide a kit for predicting (diagnosing) the therapeutic effect or prognosis of a lung cancer patient using Pemetrexed, comprising the marker.

[0014] Another objective of the present invention is to provide a method for predicting the therapeutic effect or prognosis of pemetrexed anticancer chemotherapy using the polymorphism of EXO1. means of solving the problem

[0015] To achieve the above objective, the present invention provides a polynucleotide for predicting the therapeutic effect or prognosis of Pemetrexed or a polynucleotide complementary thereto comprising a nucleotide at a specific position of SEQ ID NO. 1.

[0016] To achieve the above objective, the present invention provides a composition comprising a polynucleotide for predicting a Pemetrexed therapeutic effect or prognosis, comprising the polynucleotide and a polypeptide encoded by the same, or a polynucleotide complementary thereto.

[0017] In addition, the present invention provides a microarray for predicting the therapeutic effect or prognosis of Pemetrexed, comprising the polynucleotide and the polypeptide encoded by it.

[0018] In addition, the present invention provides a kit for predicting the therapeutic effect or prognosis of Pemetrexed, comprising the microarray.

[0019] In addition, the present invention provides a method for predicting the therapeutic effect or prognosis of Pemetrexed using the polynucleotide and the polypeptide encoded by it. Effects of the invention

[0020] The present invention discovers genetic factors capable of predicting the therapeutic effect and prognosis of Pemetrexed by utilizing polymorphisms of microRNA target sites, and develops biomarkers.

[0021] The scope of application of this invention can be expanded to include a technology capable of discovering SNP markers that can predict the therapeutic effect or prognosis of anticancer drugs and general therapeutic agents using drugs, including new drugs, continuously in the future. Brief explanation of the drawing

[0022] Figure 1 is a figure confirming the association between the clinical results of EXO1 rs1047840 of the present invention and Pemetrexed (Alimta). Figure 2 is a figure confirming the correlation with the level of target gene expression through the measurement of Luciferase activity of EXO1 rs1047840 of the present invention. Specific details for implementing the invention

[0023] The present invention will be described in detail below with reference to embodiments thereof. However, the following embodiments are presented as examples of the present invention and are not intended to limit the present invention, and various modifications and applications are possible within the scope of the claims set forth below and the equivalent scope interpreted therefrom.

[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention pertains. Any method and material similar or equivalent to those described herein may be used in practice to test the invention, but preferred materials and methods are described herein.

[0025] In the present invention, the term “comprising” any component means that, unless specifically stated otherwise, it does not exclude other components but may include additional components.

[0026] The present invention provides a polynucleotide for predicting the therapeutic effect or prognosis of Pemetrexed or a polynucleotide complementary thereto comprising a nucleotide at a specific position of SEQ ID NO. 1.

[0027] More specifically, the present invention provides a marker for predicting the therapeutic effect or prognosis (diagnosis) of Pemetrexed, comprising a polynucleotide in which the 143rd base of the polynucleotide of SEQ ID NO. 1 is G or A and the polynucleotide is composed of a continuous DNA sequence including said 143rd base; or a polynucleotide complementary thereto.

[0028] The present invention provides a composition for predicting the therapeutic effect or prognosis of a patient administered Pemetrexed, comprising a preparation capable of detecting an SNP of the 143rd base in a polynucleotide consisting of SEQ ID NO. 1.

[0029] The present invention provides a kit for predicting the therapeutic effect or prognosis (diagnosis) of a patient administered Pemetrexed, comprising the above composition.

[0030] The above kit can be used to predict the therapeutic effect or prognosis of Pemetrexed by identifying the EXO1 rs1047840G>A polymorphic site (SNP) within the promoter of the EXO1 gene, which is a marker for predicting the therapeutic effect or prognosis of Pemetrexed for lung adenocarcinoma. The above kit may include a polynucleotide, primer, or probe for identifying the EXO1 rs1047840G>A SNP, as well as one or more other component compositions, solutions, or devices suitable for the analysis method.

[0031] Additionally, the above kit may be a kit for predicting therapeutic effects or prognosis using Pemetrexed, comprising essential elements necessary for performing DNA chip analysis. The DNA chip kit comprises a substrate to which a specific polynucleotide, primer, or probe for the SNP is attached, and the substrate may comprise a nucleic acid corresponding to a quantitative control gene or a fragment thereof.

[0032] The present invention provides a microarray for predicting the therapeutic effect or prognosis of a patient administered Pemetrexed, comprising the above composition.

[0033] The above microarray may be composed of a conventional microarray except that it includes the polynucleotide of the present invention.

[0034] The present invention provides a method for predicting the therapeutic effect or prognosis of a patient administered Pemetrexed, comprising the step of identifying an SNP of the 143rd base in a polynucleotide consisting of SEQ ID NO. 1 from isolated nucleic acids.

[0035] More specifically, the above method for predicting therapeutic effects or prognosis may include the step of identifying the bases of a polymorphic site of a polynucleotide containing an SNP of the 143rd base in a polynucleotide consisting of SEQ ID NO. 1 in isolated nucleic acids.

[0036] The rs1047840G>A of the present invention can increase the expression level of EXO1 by changing the binding of miRNA.

[0037] In one embodiment of the present invention, if the genotype of the SNP at the 143rd base of the polynucleotide consisting of SEQ ID NO. 1 from the nucleic acid of the patient administered Pemetrexed is A, the therapeutic effect or prognosis of Pemetrexed for lung adenocarcinoma may be predicted to be poor. The nucleic acid may be obtained from samples such as tissue, cells, whole blood, serum, plasma, saliva, sputum, cerebrospinal fluid, or urine obtained from these lung cancer patients, and the nucleic acid sample includes DNA, mRNA, or cDNA synthesized from mRNA. Furthermore, the nucleic acid of the lung cancer patient may be obtained by conventional methods and separation methods such as the phenol / chloroform extraction method and the protease K treatment method, and may also be obtained by amplifying the target nucleic acid through PCR and purifying it.

[0038] Confirmation of the SNP genotype of the present invention can be performed by known methods such as sequencing analysis, sequencing analysis using an automated DNA sequencer, pyrosequencing, hybridization by microarray, PCR-RELP (restriction fragment length polymorphism), PCR-SSCP (single strand conformation polymorphism), PCR-SSO (specific sequence oligonucleotide), ASO (allele specific oligonucleotide) hybridization combining PCR-SSO and dot hybridization, TaqManPCR, MALDI-TOF / MS, RCA (rolling circle amplification), HRM (high resolution melting) method, primer extension method, Southern blot hybridization method, dot hybridization method, etc.

[0039] The results of the SNP polymorphisms of the present invention can be statistically processed using statistical analysis methods commonly used in the art, for example, by using variables such as continuous variables, categorical variables, odds ratios, and 95% confidence intervals obtained through Student's t-test, Chi-square test, linear regression line analysis, and multiple logistic regression analysis.

[0040] “EXO1” of the present invention is an abbreviation for “Exonuclease 1,” a type of Rad2 / XPG nuclease, and is a nuclease that exhibits 5’→3’ exonuclease, 5’ flap endonuclease, and 5’→3’ RNase H activity. EXO1 primarily contributes to DNA repair pathways such as mismatch repair (MMR), transcription interruption DNA synthesis (TLS), base removal repair (NER), and double linkage integrity (DSBR) at cell cycle checkpoints and after DNA replication. Dysfunction of EXO1 can impair DNA repair processes, which can lead to replication stress, genomic instability, and cancer development. Genetic mutations in EXO1 may be associated with the risk and prognosis of various types of cancer, including lung cancer, and overexpression of EXO1 may be associated with resistance to chemotherapy or radiotherapy and malignant prognosis in various types of cancer.

[0041] The polymorphic portion of EXO1 used in the present invention can be indicated as “EXO1 rs1047840G>A”.

[0042] The polynucleotide or its complementary polynucleotide according to the present invention is a polymorphic sequence. A polymorphic sequence refers to a sequence that includes a polymorphic site exhibiting a single nucleotide polymorphism within a nucleotide sequence. A polymorphic site refers to a site within a polymorphic sequence where a single nucleotide polymorphism occurs.

[0043] In this invention, the term “polymorphism” refers to the case where two or more alleles exist at a single gene locus, and among the polymorphic regions, a single nucleotide polymorphism (SNP) is defined as a region where only a single nucleotide differs from person to person.

[0044] In the present invention, the term “allele” refers to multiple types of a single gene located at the same locus on homologous chromosomes. The said alleles can be used to express polymorphism; for example, an SNP has two types of alleles.

[0045] “Pemetrexed” of the present invention is an antifolate drug primarily used for the treatment of non-small cell lung cancer (NSCLC) and also for the treatment of mesothelioma. It has the effect of interfering with DNA synthesis in cancer cells by inhibiting the synthesis of DNA and RNA by targeting three enzymes involved in the synthesis of purines and pyrimidines: thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).

[0046] In the present invention, the term “prognosis” refers to the course of a disease, such as lung cancer, including onset, recurrence, metastatic spread, and drug resistance, as well as lung cancer-induced death or the possibility of progression, and whether a cure is achieved. For the purposes of the present invention, prognosis may refer to the risk of onset, course, or survival prognosis of a lung adenocarcinoma patient administered Pemetrexed.

[0047] In the present invention, the term “prediction” relates to whether and / or possibility that a patient will survive for a specific period without cancer recurrence due to said treatment, such as chemotherapy, by responding favorably or unfavorably to said treatment.

[0048] The present invention confirmed that EXO1 rs1047840G>A is a biomarker for Pemetrexed targeted anticancer chemotherapy in 314 patients.

[0049] More specifically, the present invention confirmed that it is possible to predict the therapeutic effect or prognosis of Pemetrexed for non-small cell lung cancer (NSCLC) using EXO1 rs1047840G>A.

[0051] The present invention will be explained in more detail below through examples.

[0052] However, the following examples are intended only to clearly illustrate the technical features of the present invention, and the scope of protection of the present invention is not limited by the following examples.

[0054] <Example 1> Selection of Research Subjects

[0055] The patient group used in this study consisted of a total of 314 patients. We utilized samples from a total of 314 lung adenocarcinoma patients for whom genomic DNA samples were obtained among those who received Pemetrexed-based chemotherapy at Kyungpook National University Hospital from March 2007 to July 2015.

[0057] <Example 2> Discovery of SNPs Related to Lung Adenocarcinoma

[0058] To select lung adenocarcinoma-specific polymorphisms, candidate polymorphisms of miRNA binding sites confirmed to exist in cells were first selected using the PolymiRTS database (http: / / compbio.uthsc.edu / miRSNP) and “CLASH” data integrated into the PolymiRTS database. After extracting 24,027 SNPs, 1,574 SNPs of genes involved in human cancer were extracted using the CancerGenes database (http: / / cbio.mskcc.org / cancergenes). Among these, a total of 100 functional candidate miR-TSPs were discovered, excluding those with an allele frequency of less than 0.05 in HapMap-JPT and those with strong linkage imbalance (LD, r2 ≥ 0.8). The above genotype analysis was performed using the iPLEX® Assay and MassARRAY® System (Agena Bioscience, San Diego, CA, USA), and subsequently, genes related to various pathways associated with cancer biology (genes related to the glycolysis pathway and one-carbon metabolism pathway) were selected, and miRNA target site polymorphisms present on these genes were identified.

[0059] To analyze miR-TSPs genotypes, primers for multiplex PCR were designed using Mysequenom (https: / / www.mysequenom.com) such that the sequence length including the SNP site was 100–500 bases, and genotypes according to SNPs were investigated using Mass Array (Sequenom).

[0060] Subsequently, as shown in Figure 1, a polymorphic miRNA target site marker for predicting treatment efficacy or prognosis was discovered through clinical data and association studies on patients with lung adenocarcinoma who received Pemetrexed (Alimta) treatment after diagnosis of lung cancer.

[0062] <Example 3> Results of analysis of target gene expression levels of rs1047840 SNP

[0063] Luciferase activity was analyzed to determine whether EXO1 rs1047840G>A affects the expression level of target genes by regulating miRNA binding. A recombinant vector (psiCHECK-miR-TSPs) was constructed by inserting a fragment of a lung cancer-specific candidate poly-miRTS into the psiCHECK2 vector (Promega, Madison, WI, USA) (rs1047840). Subsequently, as shown in Figure 2, a miRNA mimic binding to the psiCHECK-miR-TSPs vector was introduced into lung cancer cell lines, and Luciferase activity was measured. Through this, it was confirmed that the effect on target genes differs depending on the polymorphisms discovered in lung cancer cells.

Claims

Claim 1 A marker composition for the therapeutic effect or prognosis prediction of non-small cell lung cancer (NSCLC) of Pemetrexed, comprising a sequence of nucleotides including the 143rd nucleotide of the rs1047840 polynucleotide of SEQ ID NO. 1 constituting a part of the EXO1 gene, wherein the non-small cell lung cancer (NSCLC) is lung adenocarcinoma. Claim 2 A marker composition for the therapeutic effect or prognosis prediction of non-small cell lung cancer (NSCLC) of Pemetrexed, wherein, in claim 1, the continuous base is 1 to 100 continuous bases. Claim 3 A composition for the therapeutic effect or prognosis prediction of non-small cell lung cancer (NSCLC) of Pemetrexed comprising a preparation capable of detecting an SNP of the 143rd base in a polynucleotide consisting of SEQ ID NO. 1, wherein the non-small cell lung cancer (NSCLC) is lung adenocarcinoma. Claim 4 A composition for the therapeutic effect or prognosis prediction of non-small cell lung cancer (NSCLC) of Pemetrexed, characterized in that, in claim 3, the agent capable of detecting the SNP is a primer capable of amplifying a polynucleotide composed of 1 to 100 consecutive bases including an SNP of the 143rd base in the polynucleotide of SEQ ID NO. 1, or a polynucleotide complementary thereof. Claim 5 delete Claim 6 delete Claim 7 A microarray for predicting the therapeutic effect or prognosis of non-small cell lung cancer (NSCLC) of Pemetrexed comprising a polynucleotide according to claim 1 or 2, a polypeptide encoded by the same, or its cDNA, wherein the non-small cell lung cancer (NSCLC) is a lung adenocarcinoma. Claim 8 A kit for predicting the therapeutic effect or prognosis of non-small cell lung cancer (NSCLC) of Pemetrexed comprising the microarray of claim 7, wherein the non-small cell lung cancer (NSCLC) is lung adenocarcinoma. Claim 9 A method for providing information for predicting the therapeutic effect or prognosis of Pemetrexed for non-small cell lung cancer (NSCLC), comprising the step of confirming the base type at the 143rd SNP position of the rs1047840 polynucleotide of SEQ ID NO. 1 constituting a part of the EXO1 gene from a separated nucleic acid sample, wherein the non-small cell lung cancer (NSCLC) is lung adenocarcinoma, and if the base at the SNP position corresponding to the 143rd nucleotide of SEQ ID NO. 1 is confirmed to be G, the therapeutic effect or prognosis of Pemetrexed for non-small cell lung cancer (NSCLC) is predicted to be superior compared to the A base of the alternative allele. Claim 10 delete Claim 11 A method for providing information for the therapeutic effect or prognosis prediction of non-small cell lung cancer (NSCLC) of Pemetrexed, wherein, in claim 9, the non-small cell lung cancer (NSCLC) is lung adenocarcinoma.

Citation Information

Patent Citations

  • DIAGNOSTIC METHODS FOR PROGNOSIS OF NON-SMALL-CELL LUNG CANCER USING BUB3, AURKB, PTTG1 AND RAD21 SNPs

    KR1020190004530A

  • Diagnostic methods for prognosis of non-small-cell lung cancer using BRD3 SNP

    KR1020220122251A